The Wall Street Journal: Over-the-counter overdose-reversal drug from nonprofit pharma group wins fast-track U.S. review

Harm Reduction Therapeutics says it plans to produce 2 million doses of 3-milligram naloxone nasal spray, called Rivive, per year.

Previous post : Eat, drink and be merry: Here’s where shoppers have been spending the most money this holiday season
Next post Why You Should Play Pickleball: The Best Sport Today